This recent transaction increases Philip Downing’s holding in the company by 31.72% to a total of $34.05K.
Based on Bioanalytical Systems’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $6.04 million and GAAP net loss of $75K. In comparison, last year the company earned revenue of $5.84 million and had a net profit of $221K. BASI’s market cap is $14.34M and the company has a P/E ratio of 49.70. Currently, Bioanalytical Systems has an average volume of 4,410.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The company operates through through the following business segments: Contract Research Services and Research Products.